Information Provided By:
Fly News Breaks for May 24, 2017
MEIP
May 24, 2017 | 16:12 EDT
Oppenheimer analyst Leah Rush Cann started MEI Pharma with an Outperform rating and $6.50 price target, estimating that two of the company's three experimental compounds, namely Pracinostat and MEI-401, could result in sales in 2022. Pracinostat could result in calendar 2023 product sales of about $704M and royalty income to MEI of nearly $127M, while MEI-401 could yield CY2023 sales to the company of about $621M, the analyst noted.
News For MEIP From the Last 2 Days
There are no results for your query MEIP
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.